Abstract
A1c (HgbA1c) were reduced by 6cm (p o 0.01) and -0.15% (p o 0.05), respectively. Improvements were also seen in triglycerides, HDL, LDL, ALT, and AST. At trial exit, IWQOL-Lite mean scores improved across all domains: þ10.5, þ14.4, þ1.9, þ9.6, þ6.9, and þ9.1 for PF, SE, SL, PD, W, and O, respectively. An improvement of greater than 7.7 in any domain is considered statistically significant. Conclusions: This study demonstrates clinically significant weight loss with ElipseTM, the first procedureless gastric balloon. The weight loss was similar to that seen in prior studies of endoscopically placed balloons. There were no serious adverse events. In addition, ElipseTM therapy led to a significant improvement in waist circumference, HgbA1c, and overall quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
